BioNexus Gene Lab (BGLC)

• Market cap: $4.11M
• 1 day: -12.80%
• 5 days: -14.59%
• 1 month: -23.70%
• 3 months: -43.31%
• 6 months: -50.24%
• Year to date: -56.17%
• 1 year: -61.53%
• 5 years: -95.30%
• 10 years: -95.30%
• Sector: Healthcare
• Industry: Medical Laboratories

About: BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Employees: 30

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

92% more capital invested

Capital invested by funds: $30.3K [Q2] → $58.2K (+$28K) [Q3]

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

33% more funds holding

Funds holding: 3 [Q2] → 4 (+1) [Q3]

0.35% more ownership

Funds ownership: 0.37% [Q2] → 0.73% (+0.35%) [Q3]